OBJECTIVES: Both diabetes mellitus and magnetic resonance image (MRI) deep white matter hyperintensities (WMHs) are more common in bipolar disorder (BD) patients than in matched controls. Deep-as opposed to periventricular--WMHs and diabetes are associated with treatment resistance and poorer outcome. This study investigated whether brain glucose metabolism by the polyol pathway--a pathway linked to nervous tissue disease in diabetes--is related to deep WMH volume and treatment resistance in BD patients. METHODS: Volumes of fluid-attenuated inversion recovery WMHs were quantified and correlated with cerebrospinal fluid (CSF) concentrations of glucose metabolites in 20 nondiabetic patients with BD and nondiabetic comparison subjects with schizophrenia (n = 15) or transient neurologic symptoms (neurologic controls, n = 15). RESULTS: BD patients, but not schizophrenic patients, had significantly greater volumes of deep but not periventricular WMHs compared to neurologic controls. BD subjects also had significantly greater CSF concentrations of sorbitol and fructose (the polyol pathway metabolites of glucose) compared to controls. Significant positive correlations between CSF metabolites and WMH volumes were found only in the BD group and were between deep WMH volumes and CSF sorbitol (rho = 0.487, p = 0.029) and fructose (rho = 0.474, p = 0.035). An index of treatment resistance correlated significantly with deep WMH volume (rho = 0.578, p = 0.008), sorbitol (rho = 0.542, p = 0.013), and fructose (rho = 0.692, p = 0.001) in BD subjects but not in other subjects. CONCLUSIONS: This is the first reported evidence of relationships between abnormal brain glucose metabolism and both deep WMHs and treatment resistance in a group of BD patients. Further studies are necessary to determine the significance of these findings to BD pathophysiology.
OBJECTIVES: Both diabetes mellitus and magnetic resonance image (MRI) deep white matter hyperintensities (WMHs) are more common in bipolar disorder (BD) patients than in matched controls. Deep-as opposed to periventricular--WMHs and diabetes are associated with treatment resistance and poorer outcome. This study investigated whether brain glucose metabolism by the polyol pathway--a pathway linked to nervous tissue disease in diabetes--is related to deep WMH volume and treatment resistance in BD patients. METHODS: Volumes of fluid-attenuated inversion recovery WMHs were quantified and correlated with cerebrospinal fluid (CSF) concentrations of glucose metabolites in 20 nondiabeticpatients with BD and nondiabetic comparison subjects with schizophrenia (n = 15) or transient neurologic symptoms (neurologic controls, n = 15). RESULTS: BD patients, but not schizophrenicpatients, had significantly greater volumes of deep but not periventricular WMHs compared to neurologic controls. BD subjects also had significantly greater CSF concentrations of sorbitol and fructose (the polyol pathway metabolites of glucose) compared to controls. Significant positive correlations between CSF metabolites and WMH volumes were found only in the BD group and were between deep WMH volumes and CSF sorbitol (rho = 0.487, p = 0.029) and fructose (rho = 0.474, p = 0.035). An index of treatment resistance correlated significantly with deep WMH volume (rho = 0.578, p = 0.008), sorbitol (rho = 0.542, p = 0.013), and fructose (rho = 0.692, p = 0.001) in BD subjects but not in other subjects. CONCLUSIONS: This is the first reported evidence of relationships between abnormal brain glucose metabolism and both deep WMHs and treatment resistance in a group of BD patients. Further studies are necessary to determine the significance of these findings to BD pathophysiology.
Authors: M P Vawter; H Tomita; F Meng; B Bolstad; J Li; S Evans; P Choudary; M Atz; L Shao; C Neal; D M Walsh; M Burmeister; T Speed; R Myers; E G Jones; S J Watson; H Akil; W E Bunney Journal: Mol Psychiatry Date: 2006-04-25 Impact factor: 15.992
Authors: M C G Otaduy; C C Leite; M T C Lacerda; M O R Costa; F Arita; E Prado; S Rosemberg Journal: AJNR Am J Neuroradiol Date: 2006-01 Impact factor: 3.825
Authors: P B Moore; D J Shepherd; D Eccleston; I C Macmillan; U Goswami; V L McAllister; I N Ferrier Journal: Br J Psychiatry Date: 2001-02 Impact factor: 9.319
Authors: Bruce L Lambert; Chia-Hung Chou; Ken-Yu Chang; Eskinder Tafesse; William Carson Journal: Pharmacoepidemiol Drug Saf Date: 2005-06 Impact factor: 2.890
Authors: Amy C Y Lo; Alvin K H Cheung; Victor K L Hung; Chung-Man Yeung; Qing-Yu He; Jen-Fu Chiu; Stephen S M Chung; Sookja K Chung Journal: J Cereb Blood Flow Metab Date: 2007-02-07 Impact factor: 6.200
Authors: G T Berry; J V Hunter; Z Wang; S Dreha; A Mazur; D G Brooks; C Ning; R A Zimmerman; S Segal Journal: J Pediatr Date: 2001-02 Impact factor: 4.406
Authors: Sarah K Tighe; Sarah A Reading; Paul Rivkin; Brian Caffo; Barbara Schweizer; Godfrey Pearlson; James B Potash; J Raymond Depaulo; Susan S Bassett Journal: Bipolar Disord Date: 2012-12 Impact factor: 6.744
Authors: Manpreet Sehmbi; Christopher D. Rowley; Luciano Minuzzi; Flavio Kapczinski; Jacek M. Kwiecien; Nicholas A. Bock; Benicio N. Frey Journal: J Psychiatry Neurosci Date: 2019-03-01 Impact factor: 6.186
Authors: Ariel Gildengers; Curtis Tatsuoka; Christopher Bialko; Kristin A Cassidy; Rayan K Al Jurdi; Laszlo Gyulai; Benoit H Mulsant; Robert C Young; Martha Sajatovic Journal: J Geriatr Psychiatry Neurol Date: 2012-03 Impact factor: 2.680
Authors: Joanne H Huang; Shaunna S Berkovitch; Jonathan Iaconelli; Bradley Watmuff; Hyoungjun Park; Shrikanta Chattopadhyay; Donna McPhie; Dost Öngür; Bruce M Cohen; Clary B Clish; Rakesh Karmacharya Journal: Mol Neuropsychiatry Date: 2016-06-24
Authors: Martin J Lan; Natalie Hesselgrave; Adam Ciarleglio; R Todd Ogden; Gregory M Sullivan; J John Mann; Ramin V Parsey Journal: Synapse Date: 2013-06-17 Impact factor: 2.562
Authors: Celien Tigchelaar; Mark L van Zuylen; Abraham H Hulst; Benedikt Preckel; André P van Beek; Ido P Kema; Jeroen Hermanides; Anthony R Absalom Journal: Diabetologia Date: 2022-04-05 Impact factor: 10.460